



## BIBLIOGRAPHY

# Briefing and Recommendations of the Global Scientific Panel on AMR and TB

The Global Scientific Panel on AMR and TB is composed of scientific and clinical leaders from over 25 UN Member States. Panel members collaborated over the course of four months to consider intersections between the public health responses to tuberculosis (TB), the world's deadliest infectious disease, and antimicrobial resistance (AMR), one of the world's biggest public health threats.

They published their findings and recommendations in May 2024, urging world leaders to break down siloes and leverage synergies at the forthcoming United Nations High-Level Meeting on AMR in September 2024. The full white paper can be accessed by visiting [www.cghproject.org/globalamrtbpanel](http://www.cghproject.org/globalamrtbpanel)

In hard copy editions of the white paper, the bibliography was not included to save on paper. The full list of over 100 references is therefore provided in this virtual bibliography.

---

<sup>1</sup> WHO (2015) Global Action Plan on Antimicrobial Resistance.

<https://www.who.int/publications/i/item/9789241509763>

<sup>2</sup> GBD 2019 Antimicrobial Resistance Collaborators (2022) Global burden of antimicrobial resistance in 2019: a systematic analysis. *The Lancet*. 399:10325.

[https://doi.org/10.1016/S0140-6736\(21\)02724-0](https://doi.org/10.1016/S0140-6736(21)02724-0)

<sup>3</sup> Dheda et al (2023) Multidrug-resistant tuberculosis. *Nature Reviews Disease Primers*. 10:22.

<https://doi.org/10.1038/s41572-024-00504-2>

<sup>4</sup> WHO (2023) Global TB Report. <https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2023>

<sup>5</sup> Stop TB Partnership (2023) Global Plan to End TB 2023–2030. Geneva.

<https://www.stoptb.org/global-plan-to-end-tb/global-plan-to-end-tb-2023-2030>

<sup>6</sup> Husain & Kashyap (2023) Double trouble: compounding effects of COVID-19 pandemic and antimicrobial resistance on drug resistant Tb epidemiology in India. *Frontiers in Public Health*. Volume 11: World TB Day Issue. <https://doi.org/10.3389/fpubh.2023.1305655>

<sup>7</sup> AMR Review (2016) Tackling drug-resistant infections globally: inal report and recommendations. Chair: Lord Jim O'Neill. [https://amr-review.org/sites/default/files/160525\\_Final%20paper\\_with%20cover.pdf](https://amr-review.org/sites/default/files/160525_Final%20paper_with%20cover.pdf)

[https://amr-review.org/sites/default/files/160525\\_Final%20paper\\_with%20cover.pdf](https://amr-review.org/sites/default/files/160525_Final%20paper_with%20cover.pdf)

<sup>8</sup> Interagency Coordination Group on Antimicrobial Resistance (2019) No time to wait: Securing the future from drug-resistant infections. Report to the Secretary General of the United Nations. <https://www.who.int/docs/default-source/documents/no-time-to-wait-securing-the-future-from-drug-resistant-infections-en.pdf>

<sup>9</sup> Handel et al (2018) Exploring the role of immune response in preventing antimicrobial resistance. *Journal of Theoretical Biology*. 256(4): 655 – 662.

<https://doi.org/10.1016%2Fj.jtbi.2008.10.025>

- 
- <sup>10</sup> Carwile et al (2022) Undernutrition is feeding the tuberculosis pandemic: A perspective. *Journal of Clinical Tuberculosis and Other Mycobacterial Diseases*. 27:100311. <https://doi.org/10.1016%2Fj.jctube.2022.100311>
- <sup>11</sup> Perez-Escamilla & Engmann (2019) Integrating nutrition services into health care system platforms: Where are we and where do we go from here. *Maternal and Child Nutrition*. 15:e1274. <https://doi.org/10.1111%2Fmcn.12743>
- <sup>12</sup> Ceglielski et al (2021) Antimicrobial drug resistance and infection prevention/control: lessons from tuberculosis. *International Journal of Infection Control*. Vol 17. <https://doi.org/10.3396/ijic.v17.20840>
- <sup>13</sup> Yates et al. (2023) Time to change the way we think about tuberculosis infection prevention and control in health facilities: insights from recent research. *Antimicrobial Stewardship & Healthcare Epidemiology*. 3:1. <https://doi.org/10.1017/ash.2023.192>
- <sup>14</sup> Baljin, Bayaraa & Gurjav, Ulziijargal & Tulгаа, Khosbayar & Baldan, Ganbaatar & Gunchin, Batbaatar & Sandag, Tsogtsaikhan & Pfeffer, Klaus & Wendel, Andreas & Mackenzie, Colin. (2021). High Acquisition Rate of Gram-Negative Multi-Drug Resistant Organism Colonization During Hospitalization: A Perspective from a High Endemic Setting. *Infection and Drug Resistance*. Volume 14. 3919–3927. 10.2147/IDR.S328139.
- <sup>15</sup> WHO (2022) Global Report on Infection Prevention and Control. <https://www.who.int/publications/i/item/9789240051164>
- <sup>16</sup> WHO (2022) Global Strategy on Infection Prevention and Control. Seventy-Fifth World Health Assembly. A75/A/CONF./5. <https://www.who.int/teams/integrated-health-services/infection-prevention-control/draft-global-action-plan-and-monitoring-framework-on-ipc>
- <sup>17</sup> Martinez et al (2022) Infant BCG vaccination and risk of pulmonary and extrapulmonary tuberculosis throughout the life course: a systematic review and individual participant data meta-analysis. *Lancet Global Health*. 10(9):e1307–1316. [https://doi.org/10.1016/S2214-109X\(22\)00283-2](https://doi.org/10.1016/S2214-109X(22)00283-2)
- <sup>18</sup> Micoli et al (2021) The role of vaccines in combatting antimicrobial resistance. *Nature Reviews of Microbiology*. 19:287–302. <https://doi.org/10.1038/s41579-020-00506>
- <sup>19</sup> WHO (2023) Global TB Report. Geneva. <https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2023>
- <sup>20</sup> WHO, FAO & OIE (2020) Technical brief on water, sanitation, hygiene and wastewater management to prevent infections and reduce the spread of antimicrobial resistance. <https://iris.who.int/bitstream/handle/10665/332243/9789240006416-eng.pdf?sequence=1>
- <sup>21</sup> Global Goals (2023) Goal 6: Clean Water and Sanitation. <https://www.globalgoals.org/goals/6-clean-water-and-sanitation/>
- <sup>22</sup> Sambaza & Naiker (2023) Contribution of wastewater to antimicrobial resistance: A review article. *Journal of Global Antimicrobial Resistance*. 34: 23–29. <https://doi.org/10.1016/j.jgar.2023.05.010>
- <sup>23</sup> WHO & Unicef (2021) Global progress report on WASH in health care facilities: fundamentals first. <https://www.who.int/publications/i/item/9789240017542>

- 
- <sup>24</sup> WHO, FAO & OIE (2020) Technical brief on water, sanitation, hygiene and wastewater management to prevent infections and reduce the spread of antimicrobial resistance. <https://iris.who.int/bitstream/handle/10665/332243/9789240006416-eng.pdf?sequence=1>
- <sup>25</sup> WHO, OIE, FAO, the Union (2017) Roadmap for Zoonotic Tuberculosis. Geneva. <https://www.woah.org/app/uploads/2021/03/roadmap-zoonotic-tb.pdf>
- <sup>26</sup> Maharjan et al (2021) A scoping review on climate change and tuberculosis. International Journal of Biometeorology. 65:1579–1595. <https://doi.org/10.1007/s00484-021-02117-w>
- <sup>27</sup> Flores-Lopez CA, Zenteno-Cuevas R, Laniado-Laborin R, Reynaud Y, Garcia-Ortiz RA, Gonzalez YMJA, et al. Molecular epidemiology of Mycobacterium tuberculosis in Baja California, Mexico: A result of human migration? Infection, Genetics and Evolution. 2017;55:378–83. <https://doi.org/10.1016/j.meegid.2016.07.001>
- <sup>28</sup> Dominguez et al (2023) Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a 2023 TBnet/RESIST-TB consensus statement. Lancet Infectious Diseases. 23(4):e122–e137. [https://doi.org/10.1016/s1473-3099\(22\)00875-1](https://doi.org/10.1016/s1473-3099(22)00875-1)
- <sup>29</sup> WHO (2022) Global antimicrobial resistance and use surveillance system (GLASS) report: 2022. <https://www.who.int/publications/i/item/9789240062702>
- <sup>30</sup> WHO (2022) Global AMR Data Dashboard – Glass Antimicrobial Resistance and Use Surveillance System. [https://worldhealthorg.shinyapps.io/glass-dashboard/\\_w\\_d1ce40df/#!/amr](https://worldhealthorg.shinyapps.io/glass-dashboard/_w_d1ce40df/#!/amr)
- <sup>31</sup> WHO (2023) Global TB Report. Geneva. <https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2023>
- <sup>32</sup> Dean et al (2022) 25 years of surveillance of drug-resistant tuberculosis: Achievements, challenges and the way forward. Lancet Infectious Diseases. 22:7. [https://doi.org/10.1016%2FS1473-3099\(21\)00808-2](https://doi.org/10.1016%2FS1473-3099(21)00808-2)
- <sup>33</sup> Tagliani et al (2021) Use of whole genome sequencing-based approach for Mycobacterium tuberculosis surveillance in Europe in 2017–2019: an ECDC pilot study. European Respiratory Journal. 57:2002272. <https://doi.org/10.1183/13993003.02272-2020>
- <sup>34</sup> WHO (2023) The use of next generation sequencing for the surveillance of drug-resistant tuberculosis: an implementation manual. Geneva. <https://www.who.int/publications/i/item/9789240078079>
- <sup>35</sup> Bertagnolio et al (2023) Antimicrobial resistance: Strengthening surveillance for public health action. PLoS Med. 20:7. <https://doi.org/10.1371%2Fjournal.pmed.1004265>
- <sup>36</sup> Hasan et al (2018) Integrating tuberculosis and antimicrobial resistance control programmes. Bulletin of the World Health Organization. 96(3): 194–200. <https://doi.org/10.2471%2FBLT.17.198614>
- <sup>37</sup> WHO (2022) Global AMR Data Dashboard – Glass Antimicrobial Resistance and Use Surveillance System. [https://worldhealthorg.shinyapps.io/glass-dashboard/\\_w\\_d1ce40df/#!/amr](https://worldhealthorg.shinyapps.io/glass-dashboard/_w_d1ce40df/#!/amr)
- <sup>38</sup> Bertagnolio et al. (2023) Antimicrobial resistance: Strengthening surveillance for public health action. PLoS Med. Volume 20, Issue 7. <https://doi.org/10.1371%2Fjournal.pmed.1004265>

- 
- <sup>39</sup> WHO (2021) Guidance for the surveillance of drug resistance in tuberculosis: Sixth edition. <https://www.who.int/publications/i/item/9789240018020>
- <sup>40</sup> Ajulo et al (2024) Global antimicrobial resistance and use surveillance system (GLASS 2022); Investigating the relationship between antimicrobial resistance and antimicrobial consumption data across participating countries. PLoS One. 19(2): e0297921. <https://doi.org/10.1371/journal.pone.0297921>
- <sup>41</sup> WHO (2022) Global AMC Data Dashboard – Global Antimicrobial Resistance and Use Surveillance System. [https://worldhealthorg.shinyapps.io/glass-dashboard/\\_w\\_d1ce40df/#!/amc](https://worldhealthorg.shinyapps.io/glass-dashboard/_w_d1ce40df/#!/amc)
- <sup>42</sup> WHO (2022) Global Antimicrobial Resistance and use surveillance system (GLASS) report 2022. <https://www.who.int/publications/i/item/9789240062702>
- <sup>43</sup> Fleming et al (2021) The Lancet Commission on diagnostics: transforming access to diagnostics. 398: 10315. [https://doi.org/10.1016/S0140-6736\(21\)00673-5](https://doi.org/10.1016/S0140-6736(21)00673-5)
- <sup>44</sup> WHO (2023) Global TB Report. Geneva. <https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2023>
- <sup>45</sup> Lazarchik et al. (2022) Global availability of susceptibility testing for second-line anti-tuberculosis agents. International Journal of Tuberculosis and Lung Disease. 26:6. <https://doi.org/10.5588/ijtld.21.0420>
- <sup>46</sup> Kwak N, Winters N, Campbell JR, Chan ED, Gegia M, Lange C, Lee M, Milanov V, Menzies D, Yim JJ. Changes in treatment for multidrug-resistant tuberculosis according to national income. Eur Respir J. 2020 Nov 5;56(5):2001394. doi: 10.1183/13993003.01394-2020
- <sup>47</sup> Van Rie et al (2022) Balancing access to BPaLM regimens and risk of resistance. The Lancet Infectious Diseases. 22:10. [https://doi.org/10.1016/S1473-3099\(22\)00543-6](https://doi.org/10.1016/S1473-3099(22)00543-6)
- <sup>48</sup> Derendinger et al (2023) Bedaquiline resistance in patients with drug-resistant tuberculosis in Cape Town, South Africa: a retrospective longitudinal cohort study. Lancet Microbe. 4:e972-82. [https://doi.org/10.1016/S2666-5247\(23\)00172-6](https://doi.org/10.1016/S2666-5247(23)00172-6)
- <sup>49</sup> Barilar et al (2024) Emergence of bedaquiline resistant tuberculosis and of multi-drug resistant tuberculosis and extensively drug resistant tuberculosis strains with rboB Ile491Phe mutation not detected by Xpert MTB/RIF in Mozambique. A retrospective observational study. The Lancet Infectious Diseases, 23:3, [https://doi.org/10.1016/S1473-3099\(23\)00498-X](https://doi.org/10.1016/S1473-3099(23)00498-X)
- <sup>50</sup> Lange et al (2023) Emerging bedaquiline-resistant tuberculosis. Lancet Microbe. 4:12. [https://doi.org/10.1016/S2666-5247\(23\)00321-X](https://doi.org/10.1016/S2666-5247(23)00321-X)
- <sup>51</sup> Nimmo C et al (2024) Detection of a historic reservoir of bedaquiline/clofazimine resistance-associated variants in Mycobacterium tuberculosis. Genome Med. 19;16(1):34. doi: 10.1186/s13073-024-01289-5
- <sup>52</sup> Köser et al (2019) Those who cannot remember the past are condemned to repeat it: drug-susceptibility testing for bedaquiline and delamanid. International Journal of Infectious Diseases. 80:S32-S35. <https://doi.org/10.1016/j.ijid.2019.02.027>
- <sup>53</sup> Günther G et al (2023). Availability of drugs and resistance testing for BPaLM regimen for rifampicin-resistant tuberculosis in Europe. Clin Microbiol Infect. 2024 Mar 13:S1198-743X(24)00121-6. doi: 10.1016/j.cmi.2024.03.009.

- 
- <sup>54</sup> Kao et al (2023) Strengthening health systems through essential diagnostic lists and diagnostic network optimization. *PLoS Global Public Health*. 3(3):e0001773.  
<https://doi.org/10.1371%2Fjournal.pgph.0001773>
- <sup>55</sup> WHO (2023) Strengthening Diagnostics Capacity.  
[https://apps.who.int/gb/ebwha/pdf\\_files/WHA76/A76\\_R5-en.pdf](https://apps.who.int/gb/ebwha/pdf_files/WHA76/A76_R5-en.pdf)
- <sup>56</sup> Miller et al (2023) Pharmacy engagement in TB prevention and care: not if, but how? *BMJ Global Health*. 8:7. <https://doi.org/10.1136/bmjgh-2023-013104>
- <sup>57</sup> Ali et al (2023) Partnering with private laboratories so strengthen TB diagnostics in Nigeria. *Journal of Clinical Tuberculosis and other Mycobacterial Diseases*. 31: 100369.  
<https://doi.org/10.1016%2Fj.jctube.2023.100369>
- <sup>58</sup> Linaza, Rocio & Genovezos, Chantelle & Garner, Timothy & Panford-Quainoo, Edwin & Roberts, Adam. (2022). Global antimicrobial stewardship and the need for pharmaceutical system strengthening for antimicrobials within a One Health approach. *The International journal of pharmacy practice*. 30. 10.1093/ijpp/riac012.
- <sup>59</sup> Mendelson et al (2023) Antimicrobial resistance and the great divide: inequity in priorities and agendas between the Global North and the Global South threatens global mitigation of antimicrobial resistance. *Lancet Global Health*. 12:3. [https://doi.org/10.1016/S2214-109X\(23\)00554-5](https://doi.org/10.1016/S2214-109X(23)00554-5)
- <sup>60</sup> WHO (2024) Global burden of preventable medication-related harm in health care: a systematic review. <https://www.who.int/publications/i/item/9789240088887>
- <sup>61</sup> WHO (2022) The WHO AWaRE (Access, Watch, Reserve) antibiotic book. Geneva.  
<https://www.who.int/publications/i/item/WHO-MHP-HPS-EML-2022.02>
- <sup>62</sup> Akalu TY et al (2023) Economic burden of multi-drug resistant tuberculosis on patients and households: a global systematic review and meta-analysis. *Scientific Reports*. Volume 13: 22361. <https://doi.org/10.1038%2Fs41598-023-47094-9>
- <sup>63</sup> Dixon et al (2023) No action without its side effects: Adverse drug reactions and missed doses of antituberculosis therapy, a scoping review. *British Journal of Clinical Pharmacology*. 9: 313-320. <https://doi.org/10.1111%2Fbcpc.15908>
- <sup>64</sup> Souza, L.L.L., Santos, F.L.d., Crispim, J. et al. Causes of multidrug-resistant tuberculosis from the perspectives of health providers: challenges and strategies for adherence to treatment during the COVID-19 pandemic in Brazil. *BMC Health Serv Res* 21, 1033 (2021).  
<https://doi.org/10.1186/s12913-021-07057-0>
- <sup>65</sup> WHO (2022) The WHO AWaRE (Access, Watch, Reserve) antibiotic book. Geneva, Switzerland: WHO, Available at: <https://www.who.int/publications/i/item/9789240062382>
- <sup>66</sup> Hanset et al (2017) Finding the missing patients with tuberculosis. Lessons learned from patient pathway analyses in 5 countries. *Journal of Infectious Diseases*. 216(7): S686-695.  
<https://doi.org/10.1093/infdis/jix388>
- <sup>67</sup> Oeser et a (2023) Digital approaches to reducing TB treatment loss to follow-up. *International Journal of Tuberculosis and Lung Disease*. 27:6.  
<https://doi.org/10.5588/ijtld.23.0027>

- 
- <sup>68</sup> Akalu TY et al (2023) Economic burden of multi-drug resistant tuberculosis on patients and households: a global systematic review and meta-analysis. *Scientific Reports*. Volume 13: 22361. <https://doi.org/10.1038%2Fs41598-023-47094-9>
- <sup>69</sup> Assefa DG (2024) Financial burden of tuberculosis diagnosis and treatment for patients in Ethiopia: a systematic review and meta-analysis. *BMC Public Health*. Volume 24. <https://doi.org/10.1186%2Fs12889-024-17713-9>
- <sup>70</sup> Linh N N et al (2020) No universal access to drug-resistant tuberculosis care without engaging all health care providers. *International Journal of Tuberculosis and Lung Disease* Volume 24, Issue 1. <https://doi.org/10.5588/ijtld.19.0436>
- <sup>71</sup> Sulis G et al (2020) Antibiotic overuse in the primary health care setting: a secondary data analysis of standardised patient studies from India, China and Kenya. *BMJ Global Health*, Volume 5:e003393 <https://doi.org/10.1136/bmjgh-2020-003393>
- <sup>72</sup> Jinxi L et al (2023) Worldwide dispensing of non-prescription antibiotics in community pharmacies and associated factors: a mixed methods systematic review. *Lancet Infectious Diseases*, Volume 23, Issue 9. [https://doi.org/10.1016/S1473-3099\(23\)00130-5](https://doi.org/10.1016/S1473-3099(23)00130-5)
- <sup>73</sup> WHO (2024) Global burden of preventable medication-related harm in health care: a systematic review. <https://www.who.int/publications/i/item/9789240088887>
- <sup>74</sup> Khan et al (2024) Caught in each other's traps: factors perpetuating incentive-linked prescribing deals between physicians and the pharmaceutical industry. *International Journal of Health Policy and Management*. <https://doi.org/10.34172/ijhpm.2024.8213>
- <sup>75</sup> Günther G, Guglielmetti L, Leu C, Lange C, van Leth F; Tuberculosis Network European Trials group. Availability and costs of medicines for the treatment of tuberculosis in Europe. *Clin Microbiol Infect*. 2023 Jan;29(1):77-84. doi: 10.1016/j.cmi.2022.07.026. Epub 2022 Aug 10. PMID: 35961488; PMCID: PMC9801521.
- <sup>76</sup> Guglielmetti L et al (2022) Rifapentine access in Europe: growing concerns over key tuberculosis treatment component. *Eur Respir J*. 2022 May 19;59(5):2200388. doi: 10.1183/13993003.00388-2022.
- <sup>77</sup> Rodriguez et al (2019) Barriers and facilitators of early access to bedaquiline and delamanid for MDR-TB: a mixed methods study. *Public Health Action* 9(1): 32-41. <https://doi.org/10.5588%2Fpha.18.0078>
- <sup>78</sup> WHO (2017) A study on the public health and socioeconomic impact of substandard and falsified medical products. Geneva. Available online: <https://www.who.int/publications/i/item/9789241513432>
- <sup>79</sup> WHO (2022) The WHO Member State Mechanism on Substandard and Falsified Medical Products. Update 2022. Geneva. Available online: <https://www.who.int/publications/i/item/WHO-MHP-RPQ-REG-2022.01>
- <sup>80</sup> Bam et al (2017) Reducing stock-outs of essential tuberculosis medicines: a system dynamics modelling approach to supply chain management. *Health Policy and Planning*. 32(8): 1127-1134. <https://doi.org/10.1093/heapol/czx057>
- <sup>81</sup> Shafiq et al (2021) Shortage of essential antimicrobials: a major challenge to global health security. *BMJ Global Health*. 6(11): e006961. <https://doi.org/10.1136%2Fbmjgh-2021-006961>

- 
- <sup>82</sup> WHO (2023) Global research agenda for antimicrobial resistance in human health. Geneva. <https://www.who.int/publications/m/item/global-research-agenda-for-antimicrobial-resistance-in-human-health>
- <sup>83</sup> Treatment Action Group (2023) Tuberculosis Research Funding Trends 2005 – 2022. <https://www.treatmentactiongroup.org/resources/tbrd-report/tbrd-report-2023/>
- <sup>84</sup> WHO (2020) Global strategy for tuberculosis research and innovation. Geneva. Available online: <https://www.who.int/publications/i/item/9789240010017>
- <sup>85</sup> WHO (2023) Global research agenda for AMR in human health. <https://www.who.int/publications/m/item/global-research-agenda-for-antimicrobial-resistance-in-human-health>
- <sup>86</sup> Mancuso et al (2023) Tackling drug-resistant tuberculosis: New challenges from the old pathogen mycobacterium tuberculosis. *Microorganisms*. 11:9. <https://doi.org/10.3390/microorganisms11092277>
- <sup>87</sup> CRYPTIC Consortium (2022). A data compendium associating the genomes of 12,289 *Mycobacterium tuberculosis* isolates with quantitative resistance phenotypes to 13 antibiotics. *Plos Biology* 2022. 20 (8), e3001721
- <sup>88</sup> Gurjav (2016) Transmission of multi-drug resistant tuberculosis in Mongolia is driven by Beijing strains of mycobacterium tuberculosis resistant to all first line drugs. *Tuberculosis*. 101: 49–53. <https://doi.org/10.1016/j.tube.2016.07.010>
- <sup>89</sup> Cheng-Yen Kao, Uuganbayar Udval, Hsiu-Mei Wu, Enkhbaatar Bolormaa, Jing-Jou Yan, Tulgaa Khosbayar, Jiunn-Jong Wu. “First characterization of fluoroquinolone resistance mechanisms in CTX-M-producing *Escherichia coli* from Mongolia”, *Infection, Genetics and Evolution* 38 (2016) 79–81
- <sup>90</sup> Van Rie et al (2022) Balancing access to BPaLM regimens and risk of resistance. *The Lancet Infectious Diseases*. 22:10. [https://doi.org/10.1016/S1473-3099\(22\)00543-6](https://doi.org/10.1016/S1473-3099(22)00543-6)
- <sup>91</sup> Derendinger et al (2023) Bedaquiline resistance in patients with drug-resistant tuberculosis in Cape Town, South Africa: a retrospective longitudinal cohort study. *Lancet Microbe*. 4:e972–82. [https://doi.org/10.1016/S2666-5247\(23\)00172-6](https://doi.org/10.1016/S2666-5247(23)00172-6)
- <sup>92</sup> Barilar et al (2024) Emergence of bedaquiline resistant tuberculosis and of multi-drug resistant tuberculosis and extensively drug resistant tuberculosis strains with rboB Ile491Phe mutation not detected by Xpert MTB/RIF in Mozambique. A retrospective observational study. *The Lancet Infectious Diseases*, 23:3, [https://doi.org/10.1016/S1473-3099\(23\)00498-X](https://doi.org/10.1016/S1473-3099(23)00498-X)
- <sup>93</sup> Lange et al (2023) Emerging bedaquiline-resistant tuberculosis. *Lancet Microbe*. 4:12. [https://doi.org/10.1016/S2666-5247\(23\)00321-X](https://doi.org/10.1016/S2666-5247(23)00321-X)
- <sup>94</sup> Nimmo C, Ortiz AT, Tan CCS, Pang J, Acman M, Millard J, Padayatchi N, Grant AD, O'Donnell M, Pym A, Brynildsrud OB, Eldholm V, Grandjean L, Didelot X, Balloux F, van Dorp L. Detection of a historic reservoir of bedaquiline/clofazimine resistance-associated variants in *Mycobacterium tuberculosis*. *Genome Med*. 2024 Feb 19;16(1):34. doi: 10.1186/s13073-024-01289-5



- 
- <sup>95</sup> Köser et al (2019) Those who cannot remember the past are condemned to repeat it: drug-susceptibility testing for bedaquiline and delamanid. *International Journal of Infectious Diseases*. 80:S32–S35. <https://doi.org/10.1016/j.ijid.2019.02.027>
- <sup>96</sup> Günther G et al (2023). Availability of drugs and resistance testing for BPaLM regimen for rifampicin-resistant tuberculosis in Europe. *Clin Microbiol Infect*. 2024 Mar 13:S1198–743X(24)00121–6. doi: 10.1016/j.cmi.2024.03.009.
- <sup>97</sup> Georghiou et al (2023) Designing molecular diagnostics for current tuberculosis drug regimens. *Emerging Microbes and Infections*. 12: 2178243. <https://doi.org/10.1080/22221751.2023.2178243>
- <sup>98</sup> Anthony RM et al (2023) The appearance of sugI mixed loci in three individuals during treatment for MDR-TB, supports the involvement of sugI in Mycobacterium tuberculosis d-cycloserine resistance in vivo. *BioRxiv preprint*. <https://doi.org/10.1101/2023.05.30.542839>
- <sup>99</sup> WHO (2021) 2021 Antibacterial agents in clinical and preclinical development: an overview analysis. <https://www.who.int/publications/i/item/9789240047655>
- <sup>100</sup> Perumal et al (2023) Regimens for drug-resistant tuberculosis. *New England Journal of Medicine*. 388(2): 189. <https://doi.org/10.1056/nejmc2213970>
- <sup>101</sup> V Singh (2021) Strategies to combat multi-drug resistance in tuberculosis. *Accounts of Chemical Research*. 54:10. <https://doi.org/10.1021%2Facs.accounts.0c00878>
- <sup>102</sup> Mok et al (2022) 9 months of delamanid, linezolid, levofloxacin and pyrazinamide versus conventional therapy for treatment of fluoroquinolone-sensitive multidrug-resistant tuberculosis (MDR-END): a multicentre, randomised, open-label phase 2/3 non-inferiority trial in South Korea. *Lancet*. 400:10362. [https://doi.org/10.1016/S0140-6736\(22\)01883-9](https://doi.org/10.1016/S0140-6736(22)01883-9)
- <sup>103</sup> Rao et al (2015) B in TB: B cells as mediators of clinically relevant immune response in tuberculosis. *Clinical Infectious Diseases*. 61(s3): S225–234. <https://doi.org/10.1093/cid/civ614>
- <sup>104</sup> Oved (2021) Fighting AMR with Host Immune Response Technology. *Drug Discovery Today*. 26(9): 2081–2083. <https://doi.org/10.1016%2Fj.drudis.2020.11.036>
- <sup>105</sup> WHO (2023) Global Vaccine Accelerator Council. <https://www.who.int/initiatives/tuberculosis-vaccine-accelerator-council#:~:text=The%20TB%20vaccine%20accelerator%20council,its%20legal%20status%20from%20WHO.>
- <sup>106</sup> Whittaker & Do (2023) Antimicrobial Resistance: social science approaches to be microbiosocial. In: Liamputtong (eds) *Handbook of Social Sciences in Global Public Health*. Springer. [https://doi.org/10.1007/978-3-030-96778-9\\_77-1](https://doi.org/10.1007/978-3-030-96778-9_77-1)
- <sup>107</sup> UN (1048) Universal Declaration on Human Rights. <https://www.un.org/en/about-us/universal-declaration-of-human-rights>
- <sup>108</sup> UN (1966) International Covenant on Economic, Social and Cultural Rights. <https://www.ohchr.org/en/instruments-mechanisms/instruments/international-covenant-economic-social-and-cultural-rights>
- <sup>109</sup> Perea-Jacobo R, Muñiz-Salazar R, Laniado-Laborín R, Cabello-Pasini A, Zenteno-Cuevas R, Ochoa-Terán A. Rifampin pharmacokinetics in tuberculosis-diabetes mellitus patients : a

---

pilot study from Baja California, Mexico. *Int J Tuberc Lung Dis.* 2019;23(9):1012–6.

<https://doi.org/10.5588/ijtld.18.0739>

<sup>110</sup> Stop TB Partnership (2023) Key Asks from TB Stakeholders for the UN High-Level Meeting on TB. <https://www.stoptb.org/news/launched-key-asks-tb-stakeholders-un-high-level-meeting-tb>

<sup>111</sup> AMR Collaborators (2022) Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. *Lancet.* 399(10325): 629–655. [https://doi.org/10.1016/S0140-6736\(21\)02724-0](https://doi.org/10.1016/S0140-6736(21)02724-0)

<sup>112</sup> Shringarpure et al (2023) Patient adherence to tuberculosis treatment in the Indian subcontinent: a systematic review and meta-synthesis of qualitative research. *BMJ Open.* 13:e063926. <https://doi.org/10.1136/bmjopen-2022-063926>

<sup>113</sup> Thapa et al (2024) Unlocking the potential of informal healthcare providers in tuberculosis care: insights from India. *BMJ Global Health.* Volume 9, Issue 2. <https://doi.org/10.1136/bmjgh-2024-015212>

<sup>114</sup> Santos FLd, Souza LLL, Bruce ATI, Crispim JdA, Arroyo LH, et al. (2021) Patients' perceptions regarding multidrug-resistant tuberculosis and barriers to seeking care in a priority city in Brazil during COVID-19 pandemic: A qualitative study. *PLOS ONE* 16(4): e0249822. <https://doi.org/10.1371/journal.pone.0249822>

<sup>115</sup> Poochaichote et al (2022) AMR dialogues: a public engagement initiative to shape policies and solutions on AMR in Thailand. *Wellcome Open Research.* 7(6): 188. <https://doi.org/10.12688/wellcomeopenres.17066.2>

<sup>116</sup> Mitchell et al (2023) Addressing antimicrobial resistance through community engagement: a framework for developing contextually relevant and impactful behaviour change interventions. *JAC – Antimicrobial Resistance.* 5(6):dlad124. <https://doi.org/10.1093/jac/amr%2fdlad124>

<sup>117</sup> WHO (2023) Global database for Tracking Antimicrobial resistance Country Self-Assessment Survey. <https://amrcountryprogress.org/#/map-view>

<sup>118</sup> Patel et al (2023) Measuring the global response to antimicrobial resistance, 2020–21: a systematic governance analysis of 114 countries. *Lancet Infectious Diseases,* 23:6, [https://doi.org/10.1016/S1473-3099\(22\)00796-4](https://doi.org/10.1016/S1473-3099(22)00796-4)

<sup>119</sup> Interagency Coordination Group on Antimicrobial Resistance (2019) No time to wait: Securing the future from drug-resistant infections. Report to the Secretary General of the United Nations. <https://www.who.int/docs/default-source/documents/no-time-to-wait-securing-the-future-from-drug-resistant-infections-en.pdf>